Agroyannis B, Koutsicos D, Tzanatou-Exarchou H, Varsou-Papadimitriou E, Kapetanaki A, Yatzidis H
Nephrological Center, Athens University Medical School, Aretaieon Hospital, Greece.
Int J Artif Organs. 1991 Jul;14(7):403-6.
We studied the feasibility of treating refractory anemia and post-transfusional serious hemochromatosis in a patient undergoing hemodialysis (3x4 h weekly) for fourteen years, with recombinant human erythropoietin (r-HuEPO) associated with blood-letting. Blood transfusion previously received by the patient at a rate of two units of packed red cells every month for nine years was stopped and r-HuEPO (80 U/kg b.w.) was administered i.v. at the end of each hemodialysis. When Hct increased over 30%, approximately 40 ml of blood was removed per hemodialysis session in an attempt to accelerate iron loss. Excellent control of anemia and hemochromatosis was achieved after seven months of treatment. The patient's general condition and skin pigmentation were significantly improved.
我们研究了对一位接受血液透析（每周3次，每次4小时）长达14年的患者，采用重组人促红细胞生成素（r-HuEPO）联合放血疗法治疗难治性贫血和输血后严重血色素沉着症的可行性。此前该患者已接受了9年每月输注两个单位浓缩红细胞的输血治疗，现停止输血，并在每次血液透析结束时静脉注射r-HuEPO（80 U/kg体重）。当血细胞比容超过30%时，每次血液透析大约去除40毫升血液，以加速铁流失。治疗7个月后，贫血和血色素沉着症得到了很好的控制。患者的一般状况和皮肤色素沉着有了显著改善。
